| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10596820 | Bioorganic & Medicinal Chemistry Letters | 2010 | 4 Pages |
Abstract
Novel C(3) propenylamide and propenylsulfonamide cephalosporins have been synthesized and tested for their ability to inhibit the penicillin-binding protein 2â² (PBP2â²) from Staphylococcus epidermidis and the growth of a panel of clinically relevant bacterial species, including methicillin-resistant Staphylococcus aureus (MRSA). The most potent compounds inhibited the growth of MRSA strains with minimum inhibitory concentrations (MIC) as low as 1 μg/mL. The structure-activity relationship revealed the potential for further optimization of this new cephalosporin class.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jens Pohlmann, Natalya I. Vasilevich, Andrei I. Glushkov, Laurenz Kellenberger, Stuart Shapiro, Patrick Caspers, Malcolm G.P. Page, Franck Danel,